Where does DNA Medicine Institute, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), DNA Medicine Institute, Inc. ranks #17,607 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does DNA Medicine Institute, Inc. hold?

DNA Medicine Institute, Inc. holds 16 US utility patents granted between 2015 and 2023, spanning 13 technology areas.

What is DNA Medicine Institute, Inc.'s Innovation Score?

DNA Medicine Institute, Inc. has an Innovation Score of 31.7 out of 100 (39th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does DNA Medicine Institute, Inc. focus on?

DNA Medicine Institute, Inc.'s top technology area is G01N (Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties) with 8 patents, ranking #1,791 of 7,863 assignees active in that subclass. Grants appear in 13 CPC subclasses total.

Is DNA Medicine Institute, Inc.'s patent grant rate increasing or decreasing?

DNA Medicine Institute, Inc.'s recent grant velocity is -67% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for DNA Medicine Institute, Inc.'s patents?

DNA Medicine Institute, Inc.'s patents average 9.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the DNA Medicine Institute, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

DNA Medicine Institute, Inc.

USPTO PatentsView assignee record - 16 granted patents across 13 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: G01N (Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, DNA ranks #17,607 of 49,997 tracked US assignees by granted-patent volume, with 16 patents across 13 technology areas.

#17,607
of 49,997 US assignees by volume: 39th percentile
by Innovation Score (31.7/100): 9.7
avg claims per patent: -67%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R17607 · US Corporation #17,607 · 16 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 16 grants
MID-PACK #17,607/49,997
PHOTO-FINISH Deinove
CPC-FOCUS G01N · 13 areas
INNOV-THIN 31.7/100
CLAIMS-PAR 9.7 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -67% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Deinove (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How DNA’s 31.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.8 pts (31%) Velocity 3.3 pts (10%) Breadth 12.7 pts (40%) Claim depth 5.8 pts (18%)

Qualcomm Incorporated · highest

85
DNA Medicine Institute · this assignee

32
3D Lighting… · lowest

7

What this shows DNA's Innovation Score is 31.7/100 (39th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for DNA?

Each dot is one of DNA’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). DNA’s own 9.7 claims/patent is at or below the 12.9 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

DNA vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where DNA's grants concentrate

DNA Medicine Institute, Inc. is a focused PatentsView assignee: 13 CPC subclasses with 50% of grants classified under G01N (Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties). Peak complete grant year is 2019 (5 grants) versus a trough of 1 in 2015. By volume, DNA sits between Deinove and Driflower, LLC.

DNA's three-year grant acceleration

DNA Medicine Institute, Inc. shows 3 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Deinove

16
Dentek Oral Care

16
Dingtalk Holding…

16
Ditto

16
DNP Fine Chemicals

16
Dockon

16
Dongguan Chuang L…

16
Driflower

16
DNA Medicine Inst… ◀

16

What this shows DNA holds 16 patents at rank #17,593, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near DNA

By rank, the assignees closest to #17,593 in granted patent volume.

Leaders in G01N (Investigating OR Analysing Materials BY Determining Their…)

Other assignees with the most granted patents in DNA's primary technology class.

DNA's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

32 39th percentile higher than 39% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

DNA Medicine Institute, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	6.3%
2016	1	6.3%
2017	4	25.0%
2018	1	6.3%
2019	5	31.3%
2021	1	6.3%
2022	1	6.3%
2023	2	12.5%

Which technologies does DNA Medicine Institute, Inc. patent most?

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 8

B01L - Chemical OR Physical Laboratory Apparatus FOR General USE 5

A61B - DIAGNOSIS; SURGERY; Identification 3

C08F - Macromolecular Compounds Obtained BY Reactions Only Involving Carbon-to-carbon Unsaturated Bonds 2

B05B - Spraying APPARATUS; Atomising APPARATUS; Nozzles 2

B65D - Containers FOR Storage OR Transport OF Articles OR Materials, e.g. Bags, Barrels, Bottles, Boxes, Cans, Cartons, Crates, Drums, Jars, Tanks, Hoppers, Forwarding CONTAINERS; Accessories, Closures, OR Fittings THEREFOR; Packaging ELEMENTS; Packages 2

B67D - Dispensing, Delivering OR Transferring Liquids, NOT Otherwise Provided FOR 2

C09K - Materials FOR Miscellaneous Applications, NOT Provided FOR Elsewhere 1

C08G - Macromolecular Compounds Obtained Otherwise Than BY Reactions Only Involving Unsaturated Carbon-to-carbon Bonds 1

G03F - Photomechanical Production OF Textured OR Patterned Surfaces, e.g. FOR Printing, FOR Processing OF Semiconductor DEVICES; Materials THEREFOR; Originals THEREFOR; Apparatus Specially Adapted THEREFOR; 1

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 1

B01F - Mixing, e.g. Dissolving, Emulsifying OR Dispersing 1

Y10T - Technical Subjects Covered BY Former US Classification 1

Top 13 of 13 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

DNA Medicine Institute, Inc.'s patent record in context - here's where to go next.

DNA Medicine Institute, Inc.'s lead technology class is G01N (Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties), 50% of its portfolio - see every assignee active in that class. Explore G01N
Ranked #17,607 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare DNA Medicine Institute, Inc. against Deinove, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 31.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.